scholarly journals ANÁLISIS BIOQUÍMICO DE DOS FRACCIONES CON ACCIÓN ANTICOAGULANTE DE LAS HOJAS DE Oenothera rosea “CHUPASANGRE”

2020 ◽  
Vol 86 (3) ◽  
pp. 219-230
Author(s):  
Mirtha Yarlequé ◽  
Miguel Zaldívar ◽  
Bonilla Bonilla ◽  
Armando Yarlequé
Keyword(s):  

Tradicionalmente las hojas de Oenothera rosea “chupasangre” son usadas para reducir los hematomas, por lo que, esta investigación estuvo dirigida a la evaluación de los componentes capaces de retardar la coagulación sanguínea. Del extracto etanólico de O. rosea se separó por cromatografía de capa fina en celulosa, usando etanol: agua (1:5), dos fracciones F-2 y F-5, que luego fueron preincubadas por 10 minutos con trombina y el veneno de la serpiente Lachesis muta, rico en Enzima Semejante a Trombina (EST) y luego se midió la actividad coagulante sobre plasma humano citratado y fibrinógeno bovino (Fb), así como el sustrato cromogénico BApNA. Los resultados mostraron que F-2 alargó el tiempo de coagulación sobre Fb en 58,58 % y el F-5 en 67,78 %, mientras que usando veneno los retardos fueron para F-2 10,67 % y F-5 36,27 %. Usando plasma, los valores fueron para F-2 34,14 % y F-5 70,59 %. Asimismo, empleando trombina la actividad amidolítica se redujo en F-2 48,48 % y F-5 67,32 %, mientras que con la EST de L. muta la inhibición de F-2 50,20 % y F-5 69,10%. Mediante estos ensayos in vitro se concluye que F-2 y F-5 podrían ser flavonoides anticoagulantes, con probable acción antitrombolítica.

Author(s):  
Carolina De Oliveira ◽  
Ana Paula R. Abud ◽  
Eneida Da Lozzo ◽  
Raffaello Di Bernardi ◽  
Simone De Oliveira ◽  
...  

Paracelsus once wrote: "All things are poison and nothing is without poison, only the dose permits something not to be poisonous." Latter Hahnemann formulated the law of similars, preparations which cause certain symptoms in healthy individuals if given in diluted form to patients exhibiting similar symptoms will cure it. Highly diluted natural complexes prepared according to Hahnemann’s ancient techniques may represent a new form of immunomodulatory therapy. The lack of scientific research with highly diluted products led us to investigate the in vivo and in vitro actions of commonly used medications. Here we describe the results of experimental studies aimed at verifying the effects of Mercurius solubilis, Atropa Belladonna, Lachesis muta and Bryonia alba. All medications were at 200cH dilution. Animals were maintained for 7 days and were allowed to drink the medications, which were prepared in a way that the final dilution and agitation (200cH) was performed in drinking water. The medication bottle was changed and sucussed every afternoon. Co-culture of non treated mice bone marrow cells and in vitro treated peritoneal macrophages were also performed. After animal treatment the bone marrow cells were immunophenotyped with hematopoietic lineage markers on a flow cytometer. We have determined CD11b levels on bone marrow cells after culture and co-culture with treated macrophages and these macrophages were processed to scanning electron microscopy. We have observed by morphological changes that macrophages were activated after all treatments. Mercurius solubilis treated mice showed an increase in CD3 expression and in CD11b on nonadherent bone marrow cells after co-culture with in vitro treatment. Atropa Belladonna increased CD45R and decreased Ly-6G expression on bone marrow cells after animal treatment. Lachesis muta increased CD3, CD45R and, CD11c expression and decreased CD11b ex vivo and in nonadherent cells from co-culture. Bryonia alba increased Ly-6G, CD11c and CD11b expression ex vivo and when in co-culture CD11b was increased in adherent cells as well as decreased in nonadherent cells. With these results we have demonstrated that highly diluted medications act on immune cells activating macrophages, and changing the expression profile of hematopoietic lineage markers. Highly diluted medications are less toxic and cheaper than other commonly used medications and based on our observations, it is therefore conceivable that this medications which are able to act on bone marrow and immune cells may have a potential therapeutic use in clinical applications in diseases were the immune system is affected and also as regenerative medicine as it may allow proliferation and differentiation of progenitor cells.


2020 ◽  
Vol I (2) ◽  
pp. 15-18
Author(s):  
Usha Kushwaha

Snake venom has haemolytic action on the blood and reduces the power of its coagulability, with the result that a bloody serum continue to oozes out from wound for many hours.


Peptides ◽  
2018 ◽  
Vol 102 ◽  
pp. 1-7 ◽  
Author(s):  
Ernesto Lopes Pinheiro-Júnior ◽  
Johara Boldrini-França ◽  
Luciana Mattoso Pires de Campos Araújo ◽  
Norival Alves Santos-Filho ◽  
Lusiane Maria Bendhack ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Thaisa F. S. Domingos ◽  
Laura de A. Moura ◽  
Carla Carvalho ◽  
Vinícius R. Campos ◽  
Alessandro K. Jordão ◽  
...  

Snake venoms are complex mixtures of proteins of both enzymes and nonenzymes, which are responsible for producing several biological effects. Human envenomation by snake bites particularly those of the viperid family induces a complex pathophysiological picture characterized by spectacular changes in hemostasis and frequently hemorrhage is also seen. The present work reports the ability of six of a series of 1,2,3-triazole derivatives to inhibit some pharmacological effects caused by the venoms ofBothrops jararacaandLachesis muta.In vitroassays showed that these compounds were impaired in a concentration-dependent manner, the fibrinogen or plasma clotting, hemolysis, and proteolysis produced by both venoms. Moreover, these compounds inhibited biological effectsin vivoas well. Mice treated with these compounds were fully protected from hemorrhagic lesions caused by such venoms. But, only theB. jararacaedema-inducing activity was neutralized by the triazoles. So the inhibitory effect of triazoles derivatives against somein vitroandin vivobiological assays of snake venoms points to promising aspects that may indicate them as molecular models to improve the production of effective antivenom or to complement antivenom neutralization, especially the local pathological effects, which are partially neutralized by antivenoms.


2018 ◽  
Vol 12 (4) ◽  
pp. e0006427 ◽  
Author(s):  
Stephanie Stransky ◽  
Fernanda Costal-Oliveira ◽  
Letícia Lopes-de-Souza ◽  
Clara Guerra-Duarte ◽  
Carlos Chávez-Olórtegui ◽  
...  

2018 ◽  
pp. 1149-1157
Author(s):  
Jorge Granados-Zúñiga ◽  
Federico Aragón-Ortíz
Keyword(s):  

Se estudió la actividad fibrinolítica del veneno Lachesis muta stenophyrs y de su enzim fbrnogenoUtica. Ratas Wistar cateterizadas en la arteria carótida y vena yugular fueron inoculadas con el veneno Crudo o la enzima. Se monitoreó los cambios en la presión arterial, frecuencia cardiaca y electrocardiograma. La enzima indujo una mayor reducción del fibrinógeno que el veneno crudo, sin causar alteraciones cardiovasculares o histológicas. In vitro el veneno crudo coaguló la sangre mientras que la enzima redujo el fibrinógeno en un 23%. Los resultados sugieren el lo potencial de la enzima fbrnognoIíica como agente antitrombótico.


Toxicon ◽  
2011 ◽  
Vol 57 (4) ◽  
pp. 580-585 ◽  
Author(s):  
Karinne Cristinne da Silva Cunha ◽  
André Lopes Fuly ◽  
Elizabeth Giestal de Araujo

2022 ◽  
Vol 12 ◽  
Author(s):  
Pamella G. Gutierres ◽  
Diego R. Pereira ◽  
Nataly L. Vieira ◽  
Lilian F. Arantes ◽  
Nelson J. Silva ◽  
...  

Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced by snake venoms. In this study, we examined the action of VPL on the coagulant, haemorrhagic and enzymatic activities of Lachesis muta rhombeata (South-American bushmaster) venom. Conventional colorimetric enzymatic assays were performed for PLA2, caseinolytic and esterasic activities; in vitro coagulant activities for prothrombin time (PT) and activated partial thromboplastin time (aPTT) were performed in rat citrated plasma through a quick timer coagulometer, whereas the dimensions of haemorrhagic haloes obtained after i.d. injections of venom in Wistar rats were determined using ImageJ software. Venom (1 mg/ml) exhibited accentuated enzymatic activities for proteases and PLA2in vitro, with VPL abolishing the PLA2 activity from 0.01 mM; VPL did not affect caseinolytic and esterasic activities at any tested concentrations (0.001–1 mM). In rat citrated plasma in vitro, VPL (1 mM) alone efficiently prevented the venom (1 mg/ml)-induced procoagulant disorder associated to extrinsic (PT) pathway, whereas its association with a commercial antivenom successfully prevented changes in both intrinsic (aPTT) and extrinsic (PT) pathways; commercial antivenom by itself failed to avoid the procoagulant disorders by this venom. Venom (0.5 mg/kg)-induced hemorrhagic activity was slightly reduced by VPL (1 mM) alone or combined with antivenom (antivenom:venom ratio 1:3 ‘v/w’) in rats, with antivenom alone producing no protective action on this parameter. In conclusion, VPL does not inhibit other major enzymatic groups of L. m. rhombeata venom, with its high PLA2 antagonize activity efficaciously preventing the venom-induced coagulation disturbances.


Marine Drugs ◽  
2018 ◽  
Vol 16 (11) ◽  
pp. 412 ◽  
Author(s):  
Ana da Silva ◽  
Maria Duarte ◽  
Miguel Noseda ◽  
Luciana Ferreira ◽  
Juliana Cassolato ◽  
...  

Worldwide, snakebites have serious implications for human health. The administration of antivenom is the official treatment used to reverse the toxic activities of envenomation. However, this therapy is not efficient to treat the local effects, leading to the amputation or deformity of affected limbs. As such, alternative treatments are needed. Here, we analyze the ability of a polysaccharide from the green marine alga Gayralia oxysperma (Go3) to inhibit the effects of venom from Bothrops jararaca and Lachesis muta. B. jararaca or L. muta venoms were incubated together with sulfated heterorhamnans from Go3, and the in vitro (coagulation, proteolytic, and hemolytic) and in vivo (hemorrhagic, myotoxic, edematogenic, and lethal) activities of venoms were assessed. Additionally, Go3 was injected before and after the injection of venoms, and the toxic activities were further tested. When incubated with the venoms, Go3 inhibited all activities, though results varied with different potencies. Moreover, Go3 neutralized hemorrhagic, myotoxic, and edematogenic activities when injected before or after injection with B. jararaca and L. muta venom. Go3 also blocked the coagulation of plasma in mice caused by the venoms in an ex vivo test. Therefore, Go3 has the potential to be used as antivenom for B. jararaca and L. muta bites, notably exhibiting higher efficacy on L. muta venom.


2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Eduardo Coriolano De Oliveira ◽  
Caio Pinho Fernandes ◽  
Eladio Flores Sanchez ◽  
Leandro Rocha ◽  
André Lopes Fuly

Snake venom is composed of a mixture of substances that caused in victims a variety of pathophysiological effects. Besides antivenom, literature has described plants able to inhibit injuries and lethal activities induced by snake venoms. This work describes the inhibitory potential of ethanol, hexane, ethyl acetate, or dichloromethane extracts and fractions from stem and leaves ofManilkara subsericeaagainstin vivo(hemorrhagic and edema) andin vitro(clotting, hemolysis, and proteolysis) activities caused byLachesis mutavenom. All the tested activities were totally or at least partially reduced byM. subsericea. However, whenL. mutavenom was injected into mice 15 min first or after the materials, hemorrhage and edema were not inhibited. Thus,M. subsericeacould be used as antivenom in snakebites ofL. muta. And, this work also highlights Brazilian flora as a rich source of molecules with antivenom properties.


Sign in / Sign up

Export Citation Format

Share Document